Fortitude Family Office’s Crescent Biopharma CBIO Stock Holding History

Fortitude Family Office’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$584	Hold	40	–	–	﹤0.01%	2368
2026 Q2	$720	Hold	40	–	–	﹤0.01%	1871
2026 Q1	$735	Buy	+40	New	+$459	﹤0.01%	1589

Other funds holding CBIO

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Fortitude Family Office's CBIO Position: Q3 2026 in Review

Fortitude Family Office held its Crescent Biopharma (CBIO) position steady in Q3 2026 at 40 shares worth $584. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

Fortitude Family Office first reported a position in CBIO in Q1 2026 and has held it in 3 quarters since. The position peaked at $735 in Q1 2026. 5 funds tracked by Wall St. Rank hold CBIO as of Q3 2026.

Fortitude Family Office held 40 shares of Crescent Biopharma worth $584 as of Q3 2026.
Fortitude Family Office left its Crescent Biopharma share count unchanged in Q3 2026.
Crescent Biopharma made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2368 holding.
Fortitude Family Office first reported a position in Crescent Biopharma in Q1 2026 and has held it in 3 quarters since.
Fortitude Family Office's Crescent Biopharma position peaked at $735 in Q1 2026.
5 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.